You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | -22,990.0% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -0.3 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 252.7 | n/a |
Price / Book value | 0.9 |
Latest | Forecast | |
---|---|---|
Revenue | n/a | 0.0% |
PBT | 0.0% | n/a |
EPS | 0.0% | 0.0% |
DPS | n/a | 0.0% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2020-12-31 | n/a | -1.54 | -3.81p | -5.1 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | n/a | -1.68 | -2.34p | -15.5 | 0.0 | n/a | n/a | 0.0% |
2022-12-31 | n/a | -2.60 | -3.06p | -4.6 | 0.0 | n/a | n/a | 0.0% |
2023-12-31 | 0.01 | -2.30 | -2.01p | -2.9 | 0.0 | n/a | n/a | 0.0% |
ValiRx's Inaphaea inks deal with UK-based Screenin3D Sharecast News | 03 Feb |
---|---|
ValiRx enters evaluation and option deal with Canada's Altus Sharecast News | 29 Jan |
ValiRx further extends letter of intent with TheoremRx Sharecast News | 31 Dec |
Inaphaea Evaluation and Commercial Use Agreement | 03-Feb-25 07:01 |
---|---|
Extension of Evaluation Agreement | 30-Jan-25 07:01 |
New Evaluation and Option Agreement | 29-Jan-25 07:01 |
Holding(s) in Company | 15-Jan-25 12:47 |
Holding(s) in Company | 15-Jan-25 11:29 |